Vir Biotechnology Inc . (NASDAQ:VIR) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus estimate of $149.6 million.
Vir Biotechnology Inc . (NASDAQ:VIR) reported Q4 EPS of ($0.76), $0.41 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $49.4 million versus the consensus estimate of $149.6 million.